Citi analyst Ashiq Mubarack lowered the firm’s price target on Mersana Therapeutics to $10 from $15 and keeps a Buy rating on the shares. The company’s announcement of a partial clinical hold “comes as a complete surprise,” the analyst tells investors in a research note. Though the UpRi development risk is now increased, it remains too soon to write off the program, says the firm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRSN:
- JPMorgan downgrades Mersana after being ‘completely blindsided’
- Mersana Therapeutics downgraded to Neutral from Overweight at JPMorgan
- Mersana Therapeutics price target lowered to $10 from $16 at BTIG
- Mersana Plummets on Clinical Hold on Ovarian Cancer Trials
- Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials